Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study

The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review

“…64 Another real-world comparison of Gla-300 and iDeg in a Danish cohort of people with T2D and moderate to endstage CKD found no difference between the two BIs in terms HbA1c reduction, hospitalization for hypoglycaemia, or all-cause mortality. 66 The double-blind trial DEVOTE (N = 7637), investigated iDeg and Gla-100 in patients with T2D and a high CV risk. A secondary analysis of DEVOTE (DEVOTE 11) indicated that the lower rate of hypoglycaemia incidence in iDeg users was independent to baseline GFR, and lower baseline GFR was associated with high risk of major adverse CV events, all-cause mortality and CV death.…”

Hyperglycaemia in people with diabetes and chronic kidney disease

“…Ved forekomst af hypoglykaemi bør man overveje dosisreduktion eller skift til andet insulinregime. Risikoen for isaer natlig hypoglykaemi kan nedsaettes ved brug af de nye generationer af basalinsulinanaloger (insulin degludec og insulin glargin U100 & U300), som har vist sig sikre i behandlingen af diabetes hos personer med CKD uanset graden [19,[25][26][27]. Ligeledes er det påvist, at hurtigtvirkende (prandial/måltids-) insulinanaloger sammenlignet med humant insulin reducerer forekomsten af hypoglykaemi og giver bedre postprandial glykaemisk kontrol [17].…”